New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow ...

Mario Germano Giuliani and Lisa Giuliani have made an extraordinary gift of $27.8 million to support research in multiple myeloma, Dana-Farber Cancer Institute announced today. It is one of the ...

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.

Daraxonrasib is the first approved RAS-targeted therapy in pancreatic cancer Approval based primarily on Dana-Farber-led RASolute 302 trial showing daraxonrasib nearly doubled med ...

Grace Ho, MD is a Neuro-Oncologist at Dana-Farber Cancer Institute. She primarily treats patients with brain and spinal cord tumors including lymphoma, glioma, meningioma, ependymoma, schwannoma, ...

The U.S. Food and Drug Administration has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma, making it the first approved ...

Over $87 million has been raised through the Radio-Telethon since 2002 for Dana-Farber Cancer Institute and the Jimmy Fund WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance raised a ...

Dr. Wolpin received his medical degree from Harvard Medical School in 2001. He subsequently completed his residency in Internal Medicine at Brigham and Women's Hospital, and his fellowship in Medical ...

Our providers work together across multiple specialty areas to deliver coordinated, personalized care for patients with T-cell lymphoma — from diagnosis and treatment planning through follow-up care.

Dana-Farber’s T-Cell Lymphoma Center cares for people with T-cell lymphoma, a rare group of blood cancers that begin in T cells, a type of white blood cell. Because these cancers are uncommon and can ...